A-086 Clinical Performance of a Plasma ATN Panel for Assessment of Alzheimer's Disease

B B Collier,W C Brandon,M R Chappell,A B Harris,T Le,R L Martone,J M Volpe,D Boles,A Valcour,R P Grant

DOI: https://doi.org/10.1093/clinchem/hvae106.085

IF: 12.114

2024-10-27

Clinical Chemistry

Abstract:BackgroundIn recent years, the progression of Alzheimer's disease has widely been characterized through the utilization of an ATN classification system consisting of biomarkers for three areas of neuropathologic change: development of A myloid associated plaques, formation of neurofibrillary tangles associated with T au proteins, and onset of N eurodegeneration. However, the assessment of biomarkers related to each of these stages has predominantly relied on neuroimaging or CSF measurements which are costly and invasive. With the advent of high sensitivity immunoassays, measurements of ATN biomarkers in venous plasma has become possible and would provide a more accessible and affordable tool to assist physicians with the diagnosis of AD.MethodsAssessment of amyloid status was performed by determining the ratio of amyloid-beta 1-42 to amyloid-beta 1-40 (Aβ42/40) in plasma where measurements for individual analytes were performed in parallel on a Sysmex TM HISCL-5000 platform. Assessments of tau and neurodegeneration were performed using a Roche cobas® e801 platform to measure phosphorylated-tau181 (pTau181) and neurofilament light chain (NfL), respectively. As these assays have not yet received FDA approval, each was validated internally using CLSI guidance. The clinical efficacy of each assay was investigated using 200 clinical specimens with amyloid status defined using positron emission tomography (PET) imaging. Assay results were analyzed using receiver operator characteristic (ROC) analysis with respect to amyloid PET results. In addition, results from the clinical cohort were also assessed with respect: amyloid PET centiloid results, clinically defined cognitive status, and mental state as determined using a Mini-Mental State Exam (MMSE).ResultsROC analysis of clinical sample results from validated assays produced an area-under-the-curve (AUC) of 0.941 for Aβ42/40, 0.847 for pTau181, and 0.666 for NfL. These results are consistent with amyloid PET status as well as the progression of AD along the ATN continuum. With respect to Aβ+ subjects, Aβ42/40 results did not change due to worsening cognitive status, increasing amyloid PET results, or worsening MMSE scores. Levels of pTau181, however, were found to increase with worsening cognitive status (p < 0.01), increasing amyloid PET centiloid results (p < 0.05), as well as worsening MMSE scores (p < 0.05). In addition, NfL levels become elevated with worsening MMSE scores (p < 0.01).ConclusionsThe clinical utility of the plasma ATN panel was found to be appropriate for assisting with diagnosis of AD and is now available for physician use.

medical laboratory technology